Illumina Names Sanjay Chikarmane as SVP and General Manager
News Jul 21, 2015
Illumina Inc. has announced that Sanjay Chikarmane has been named Senior Vice President and General Manager of Illumina's Enterprise Informatics business. Chikarmane will lead the development and commercialization of products and services aimed at turning genomic data into actionable information for researchers and clinicians.
"Given the growing data intensive demands of the genomics market, we felt it critical to bring in a group leader dedicated to driving our informatics strategy," said Francis deSouza, President of Illumina. "Sanjay is an excellent addition to Illumina's leadership team and will be instrumental in growing our enterprise informatics business, defining our software development processes and service delivery architecture that will be used across all of Illumina."
Nick Naclerio who led the acquisition of NextBio and served as the founding General Manager of the Enterprise Informatics business unit will return to the full-time role of Senior Vice President of Corporate Development.
Chikarmane joins Illumina with more than 20 years of experience in enterprise software at companies including HP, BEA Systems and most recently, SAP. Through his career, he has held a variety of leadership roles in enterprise software, including general management, go-to-market, product management and product development, during which he has successfully created and scaled several market leading products.
While at SAP, Chikarmane oversaw several key products including industry solutions for big data analytics on the HANA platform, cloud business networks, data management and middleware, including their adoption by top customers.
Chikarmane holds a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology (IIT), Bombay, India and a Master of Science in Computer Engineering from Syracuse University.
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE